Pfizer launches trial of COVID-19 vaccine for infants and young children, and preliminary results are expected before the end of the year

On March 25, Pfizer stated that it has initiated clinical trials of the new crown vaccine in healthy children between 6 months and 11 years of age.
This is to obtain federal regulatory approval to start vaccinating young children and control the pandemic.
A critical step taken.

Pfizer, headquartered in New York, announced on Thursday that the first batch of participants in the vaccination trial have been vaccinated.
The program will recruit 144 children in the first phase.

For the Phase I clinical trial, the preferred dose levels for the three age groups were determined between 6 months and 2 years, 2 and 5 years, and 5 to 11 years.

Before gradually increasing the dose, children will be vaccinated with a low dose of 10μg, and participants can also choose to take a 3μg dose.

Adult new crown vaccine needs to be injected twice, each dose contains 30μg.

The company said that the researchers will evaluate the safety and effectiveness of the selected dose level in the next phase of the trial, and randomly select participants to receive the vaccine or placebo.

It said that after six months of follow-up, children who receive a placebo will have the opportunity to receive the vaccine.

It is still necessary to complete a clinical trial study in which children’s immunization tests differ from adults’ responses to test children’s vaccines.

Pfizer has launched an infant new crown vaccine trial.
Preliminary results are expected to be available before the end of the year.
Pfizer will launch an infant new crown vaccine trial before the end of the year.
Preliminary results are expected to be available before the end of the year.

Public health officials and infectious disease experts say that vaccinating children is critical to ending the pandemic.

Until children can be vaccinated, the United States is unlikely to obtain herd immunity.

According to government data, children make up about 20% of the U.
S.
population.

In late January, Pfizer stated that it had launched a full-scale trial of the new crown vaccine in children aged 12 to 15.

The company said on Thursday that the trial data was "encouraging" and expressed its desire to share more details of the trial "soon.

" Moderna also said on March 16 that it has obtained authorization for the vaccine in the United States.

The company has started a vaccination trial for children under 12 years of age.

Moderna started a testing study for children aged 12 to 17 in December.

According to the "New York Times" report, Johnson & Johnson plans to test a single shot of the vaccine in older children first, and then in infants.

The White House’s chief medical adviser, Dr.
Anthony Fauci, told the House Committee earlier this month that the United States may start vaccinating older children this fall, while elementary-age children may start vaccinating early next year.

Pfizer’s statement came two days after it stated that it had begun early clinical trials of an oral antiviral experimental drug that could be used for the initial treatment of COVID-19 infection.

Recently, the number of new cases of the new crown in the United States has shown a downward trend.
The average number of new cases in the seven days has risen to 57,695, which is 9.
5% higher than the previous week, the largest increase since January 12.

Although the Biden administration is speeding up vaccination.

So far, the number of confirmed cases of the new crown in the United States has exceeded the 30 million mark, and the death toll has exceeded 540,000.